Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> China Pharma Providers
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
China Pharma Providers
Type:
CMO-Pharma Formulation
Title:
Shenzhen Watsin Genetech Ltd
Chinese
CSertification:
GMP
International
Certification:
n/a
Primary Location:
Shenzhen
China
Contact Info:
n/a
Webpage:
www.watsin.com.cn
www.watsin-gene.com
HQ
Contact Info:
No. 7, KeJi Zhong Yi Road, Nanshan District, Shenzhen, Guangdong 518057, China
Tel: +86 755 2673 8469; 26738470 Fax: +86 755 2673 8071
Email: marketing@watsin.com.cn
Additional
Contact Info:
n/a
Description:
Watsin Company was established in 1997, with efforts offered for several years, Watsin became the first succeeded in developing EGF into a medicine in the world and became the first to be attested as a biological pharmaceutical manufacturing enterprise by passing through the State GMP.
The first rhEGF, being formally permitted to enter into the market as a medicine with the name 'GeneTime', gained its first emergence in Watsin and thus won the kind of newly emerging biological preparations in China developed independently and entirely by the enterprise's own hands.
In February of 2000, Watsin Company sponsored jointly a press conference for the entrance of the newly emerging medicine of the first class--the reorganized human epidermis growth factor derivative into the market, with the Chinese Medical Association in the Great Hall of The People while simultaneously with the announcement of nomination of the commodity as 'GeneTime' (formally being named as Yijifu).
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit